P A Minnis1,2, M Poland3, M P Keane3,4, S C Donnelly5. 1. School of Medicine and Medical Science, College of Life Sciences, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland. paul.minnis@ucd.ie. 2. National Pulmonary Fibrosis Referral Centre at St Vincent's University Hospital, Elm Park, Dublin, Ireland. paul.minnis@ucd.ie. 3. School of Medicine and Medical Science, College of Life Sciences, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland. 4. National Pulmonary Fibrosis Referral Centre at St Vincent's University Hospital, Elm Park, Dublin, Ireland. 5. Department of Medicine, Trinity Centre for Health Sciences, Tallaght Hospital, Tallaght, Dublin, Ireland.
Abstract
BACKGROUND: Ireland has one of the highest prevalence of sarcoidosis globally. Currently anti-TNF treatment in sarcoidosis is considered on a case-by-case basis particularly in patients who have a sub-optimal response to corticosteroid therapy. AIMS: We report our experience of Adalimumab in a series of refractory pulmonary sarcoidosis and discuss implications for treatment. CONCLUSION: Symptomatic improvement was found in all patients as well as stabilisation or improvement in DLCO sb. Improvements in pulmonary function tests correlated well to radiological stage and length of disease.
BACKGROUND: Ireland has one of the highest prevalence of sarcoidosis globally. Currently anti-TNF treatment in sarcoidosis is considered on a case-by-case basis particularly in patients who have a sub-optimal response to corticosteroid therapy. AIMS: We report our experience of Adalimumab in a series of refractory pulmonary sarcoidosis and discuss implications for treatment. CONCLUSION: Symptomatic improvement was found in all patients as well as stabilisation or improvement in DLCO sb. Improvements in pulmonary function tests correlated well to radiological stage and length of disease.
Authors: Nadera J Sweiss; Imre Noth; Mehdi Mirsaeidi; Wei Zhang; Edward T Naureckas; D Kyle Hogarth; Mary Strek; Philip Caligiuri; Roberto F Machado; Timothy B Niewold; Joe G N Garcia; Aileen L Pangan; Robert P Baughman Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2014-04-18 Impact factor: 0.670
Authors: S Ishioka; T Saito; K Hiyama; Y Haruta; A Maeda; S Hozawa; T Inamizu; M Yamakido Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 1996-09 Impact factor: 0.670
Authors: José Luis Callejas-Rubio; Norberto Ortego-Centeno; Lourdes Lopez-Perez; Maria Nicolas Benticuaga Journal: Clin Rheumatol Date: 2005-10-25 Impact factor: 2.980
Authors: Robert P Baughman; Marjolein Drent; Mani Kavuru; Marc A Judson; Ulrich Costabel; Roland du Bois; Carlo Albera; Martin Brutsche; Gerald Davis; James F Donohue; Joachim Müller-Quernheim; Rozsa Schlenker-Herceg; Susan Flavin; Kim Hung Lo; Barry Oemar; Elliot S Barnathan Journal: Am J Respir Crit Care Med Date: 2006-07-13 Impact factor: 21.405
Authors: James P Utz; Andrew H Limper; Sanjay Kalra; Ulrich Specks; John P Scott; Zvezdana Vuk-Pavlovic; Darrell R Schroeder Journal: Chest Date: 2003-07 Impact factor: 9.410